PLATINIUM™

ENTER A NEW ERA OF LONGEVITY.

Home Ürünlerimiz ICD devices Platinium™

World's longest lasting defibrillator backed by warranty.


Longevity calculations are based on real life pacing conditions.1
Warranty applies regardless of pacing conditions and therapy frequency.2

Platinium™ Platimium1 1

How PLATINIUM achieves its longevity?

With breakthrough technology that stands the test of time.

High battery capacity in a small size
Advanced QHR™ technology designed exclusively for ICDs.
Optimized battery volume for a higher energy density.

Reforming free capacitors
Benefits of wet tantalum capacitors include:

  • Stable charge time
  • No waste of energy due to no additional reforming

Breakthrough technology chip set

  • Nano-sized circuit
  • Reduced micro-controller and intrinsic consumption
  • 30% fewer components and improved performance*:
    - Increased storage capacity
    - Increased processing speed
*Versus previous ICD generation (Paradym RF).
Platinium™ Platimium1 1

Why longevity matters?

Need to close the gap
Over 60% of defibrillator implants take place in patients less than 70 years old3 and defibrillators patients exhibit long term survival benefits following device implant. Therefore, almost one third of the patients undergo device replacement due to battery depletion.4

Clinical burden associated with replacements
Sooner or later, the issue of replacement will arise and with it risks of serious complications.
Replacement procedures are associated with:

  • 2x occurrences of surgical reinterventions for infections or other causes.5
  • 5-fold increase ICD lead issues. 6

Healthcare costs savings
Extending device longevity has an important effect on the long-term cost of device therapy. Expected average savings per patient implanted over a 15-year time period7:

  • Up to 21% savings for ICDs from 9 to 14 years longevity
  • Up to 26% savings for CRT-Ds from 6 to 10 years longevity
Platinium™ Survival curve en 1

SonR feature is not available in the USA.

Related products: PlatiniumTM; PlatiniumTM 4LV SonRTM CRT-D; PlatiniumTM 4LV CRT-D

REFERENCES

  1. Functioning conditions for projected longevity: SonR CRT-D models: Biventricular pacing in DDD mode, 30% in atrium, 100% in both ventricles, at 60min-1, 600 ohm, A and RV pacing amplitude 2.5V, LV pacing amplitude 3V, 0.35ms, 3 max shocks per year, sensor OFF, SonR ON, MP OFF. CRT-D models: Biventricular pacing in DDD mode, 30% in atrium, 100% in both ventricles, at 60min-1, 600 ohm, A and RV pacing amplitude 2.5V, LV pacing amplitude 3V, 0.35ms, 3 max shocks per year, sensor OFF, MP OFF. DR models: Pacing in SafeR mode, 30% in atrium, 6% in ventricle, at 60min-1, 600 ohm, 2.5V, 0.35ms, 4 max shocks per year, sensor OFF. VR models: Pacing in VVI mode 6% at 40min-1, 600 ohm, 2.5V, 0.35ms, 4 max shocks per year, sensor OFF. For all models: the longevities are calculated by taking into account 6 months storage with the following conditions: Remote ON: daily check, 4 follow-ups and 5 full alert reports per year. RF telemetry ON: 45min for ICD / 120min for CRT-Ds at implant + 15min at discharge + 15min in-clinic quarterly FU.
  2. For more details please refer to the following document supplied with the device: U666 – LIMITED WARRANTY for PLATINIUM ICD and CRT-D devices.
  3. Swedish ICD and Pacemaker Registry – Annual statistic report 2014. https://www.pacemakerregistret.se/icdpmr/start.do.
  4. Ramachandra I. Impact of ICD battery Longevity on Need for Device Replacements-Insight from Veterans Affairs Database. PACE 2010; 33:314-19.
  5. Borleffs CJW, Thijssen J, Mihaly K et al. Recurrent Implantable Cardioverter-Defibrillator Replacement Is Associated with Increasing Risk of Pocket-Related Complications. Pacing Clinical Electrophysiology 2013;33:1013-19.
  6. Lovelock JD, Cruz C, Hoskins MH et al. Generator replacement is associated with an increased rate of ICD alerts. Heart Rhythm 2014;11(10):1785-89.
  7. Boriani G, Braunschweig F, Deharo JC et al. Impact of extending device longevity on the long-term costs of implantable cardioverter-defibrillator therapy: a modelling study with a 15-year time horizon. Europace 2013;15(10):1453-62.

MicroPort Türkiye web sitesinden farklı bir siteye yönlendirilmektesiniz.

Devam et